NEW YORK (360Dx) – Co-Diagnostics ended its first day as a public traded firm with its shares down about 3 percent on the Nasdaq.

The firm went public on Wednesday with an offering of more than 1.1 million shares at $6 per share. Trading on the Nasdaq Capital Market under ticker symbol CODX, its shares ended the day at $5.81 per share.

Total gross proceeds from IPO was $7.1 million, the firm said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Cancer researcher Alan Rabson has died at 92, the New York Times reports.

As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.

The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.

In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.